An application of data assimilation to mathematical biology

Eric J. Kostelich

kostelich@asu.edu



ARIZONA STATE UNIVERSITY SCHOOL OF MATHEMATICAL & STATISTICAL SCIENCES

SIAM Applied Dynamical Systems Conference Snowbird, UT May 21, 2017

- Yang Kuang, Javier Baez, ASU
- Alan Bryce, MD, Mayo Clinic Arizona

- American men have ~ 1/7 lifetime risk (~ 233,000 new cases and ~ 30,000 deaths per year)
- At diagnosis, it is difficult to distinguish aggressive tumors from indolent ones
- Overtreatment is probably common—and risky
- Prostate-specific antigen (PSA) is an imprecise proxy for cancer
- Stage C: Spread to seminal vesicles
- Stage D: Spread to lymph nodes and/or bones

• Discovered in the '30s and '40s that castration causes regression of prostate cancer tumors—thus proving that some cancers are hormone dependent



- Hormone dependence was later demonstrated for most breast cancers
- Huggins shared the 1966 Nobel Prize in Medicine for this discovery

- Castration (flutamide) remains the standard of care for locally metastatic tumors—but side effects can be debilitating
- Androgen deprivation therapy usually is very effective initally, but tumors eventually evolve resistance
- Intermittent therapy attempts to minimize side effects and forestall resistance
- The first clinical trial (Akakura et al., 1992) involved 7 patients whose serum PSA and androgen levels were measured clinically approximately once per month

Portz, Nagy, and Kuang model (2012)

- This model postulates the existence of "androgen dependent" (AD) and "androgen independent" (AI) cell populations
- Basic idea: Growth under resource constraints (Droop, 1968)
- Prostate cancer cells require a minimum level q_{\min} of androgen for survival
- Suppose $Q_1(t)$ is the cell quota for and rogen at time t

• Growth model for androgen-dependent (AD) cells:

$$\frac{dX_1}{dt} = \mu \left(1 - \frac{q_{\min}^1}{Q_1(t)} \right) X_1(t) + \text{mutations}$$

- Examples: If $Q_1(t) = 2q_{\min}^1$, then $X_1(t) \sim e^{\mu t/2}$
- $Q_1(t) = q_{\min}^1/2 \Longrightarrow X_1(t) \sim e^{-\mu t}$
- $Q_1(t) = q_{\min}^1/10 \Longrightarrow X_1(t) \sim e^{-9\mu t}$
- Of course, q_{\min}^i isn't known and probably varies by patient
- The model includes equations for $X'_{1,2}(t)$ and $Q'_{1,2}(t)$ with 19 total parameters



Prediction problem: Will another cycle of therapy be effective?

Comments on the fitting procedure

- MATLAB's fminsearch finds a set of parameters and initial conditions that fits the observations reasonably well
- Thus one can argue that the model is clinically validated

Comments on the fitting procedure

- MATLAB's fminsearch finds a set of parameters and initial conditions that fits the observations reasonably well
- Thus one can argue that the model is clinically validated
- Prediction: Another round of therapy is likely to fail

Comments on the fitting procedure

- MATLAB's fminsearch finds a set of parameters and initial conditions that fits the observations reasonably well
- Thus one can argue that the model is clinically validated
- Prediction: Another round of therapy is likely to fail
- Criticism: The procedure is *post hoc* and does not ascribe a level of confidence in the results
- Data assimilation may provide updated estimates of treatment efficacy during the course of therapy

Five necessary ingredients for data assimilation

- A dynamical forecast model
- An estimate of the forecast uncertainties
- Observations of the process under study
- Estimates of the observational errors
- A forward operator (**H** : model space \rightarrow observations)

These ingredients yield a local ensemble transform Kalman filter (LETKF)

• Androgen-dependent (AD) cells:

$$\frac{dX_1}{dt} = \mu \left(1 - \frac{q_{\min}^1}{Q_1(t)} \right) X_1(t) + \text{mutations}$$

• Androgen-independent (AI) cells:

$$\frac{dX_2}{dt} = \mu \left(1 - \frac{q_{\min}^2}{Q_2(t)} \right) X_2(t) + \text{mutations}$$

• The cell quota depends on the availability of androgen: $\frac{dQ_i}{dt} = \beta_i(A) - \gamma_i(A)Q_i, \quad i = 1, 2$

where β and γ depend on the serum and rogen level A

Ingredient #1: The Portz et al. (2012) model, 2

• PSA production:

$$\frac{dP}{dt} = \sigma_1(Q_1)X_1 + \sigma_2(Q_2)X_2 - \delta P$$

• Portz model state vector: $\mathbf{x} = (X_1, X_2, Q_1, Q_2, P)$

Ingredient #2: Estimates of forecast uncertainty

- Start with k guesses of the initial condition
- Integrate the model forward to the first forecast time (1 month in our case)
- At each model output time, we have a corresponding set of "background" state vectors

$$\left\{\mathbf{x}_{b}^{i}\right\}_{i=1}^{k}$$
 with ensemble mean $\bar{\mathbf{x}}_{b}$

• Each state vector is ℓ -dimensional ($\ell = 5$ for this model)

Ingredient #2: Estimates of forecast uncertainty, 2

- Form the $\ell \times k$ matrix \mathbf{X}_b of ensemble perturbations whose *i* th column is $\mathbf{x}_b^i - \bar{\mathbf{x}}_b$
- Let $\mathbf{w} \in \mathbb{R}^k$. Then

$$\mathbf{x} = \bar{\mathbf{x}}_b + \mathbf{X}_b \mathbf{w}$$

corresponds to a model state vector in the span of the ensemble

• For instance, $\mathbf{w} = \mathbf{e}_i$ yields $\mathbf{x} = \mathbf{x}_b^i$

Ingredient #2: Estimates of forecast uncertainty, 2

- Form the $\ell \times k$ matrix \mathbf{X}_b of ensemble perturbations whose *i* th column is $\mathbf{x}_b^i - \bar{\mathbf{x}}_b$
- Let $\mathbf{w} \in \mathbb{R}^k$. Then

$$\mathbf{x} = \bar{\mathbf{x}}_b + \mathbf{X}_b \mathbf{w}$$

corresponds to a model state vector in the span of the ensemble

- For instance, $\mathbf{w} = \mathbf{e}_i$ yields $\mathbf{x} = \mathbf{x}_b^i$
- Lemma: If **w** is Gaussian with mean **0** and covariance $(k-1)^{-1}\mathbf{I}$, then $\mathbf{x} = \bar{\mathbf{x}}_b + \mathbf{X}_b \mathbf{w}$ is Gaussian with mean $\bar{\mathbf{x}}_b$ and covariance $\mathbf{P}_b = (k-1)^{-1}\mathbf{X}_b\mathbf{X}_b^{\mathrm{T}}$

Ingredient #3: Treatment of observations

- The observations here are PSA levels (ng/mL)
- The Portz model explicitly predicts the serum PSA level
- H for this model a single component of the model state vector **x**
- In general, **H**(**x**) is an *s*-vector of predicted observations given the model state **x**
- Remember that $\mathbf{x} = \bar{\mathbf{x}}_b + \mathbf{X}_b \mathbf{w}$

Ingredient #3: Treatment of observations, 2

• Each ensemble solution yields a predicted set of observations

$$\left\{\mathbf{y}_{b}^{i}=\mathbf{H}(\mathbf{x}_{b}^{i})\right\}_{i=1}^{k}$$
 with mean $\bar{\mathbf{y}}_{b}$

- Define the $s \times k$ matrix \mathbf{Y}_b of observation perturbations whose *i* th column is $\mathbf{y}_b^i - \bar{\mathbf{y}}_b$
- In this way, we can express obervations as a function of w by linearization:

$$\mathbf{H}(\mathbf{x}) = \mathbf{H}(\bar{\mathbf{x}}_b + \mathbf{X}_b \mathbf{w}) \approx \bar{\mathbf{y}}_b + \mathbf{Y}_b \mathbf{w}$$

Ingredient #4: Estimates of observational error

- Assumption #1: The variance in the measurements is 1 ng/mL
- Assumption #2: The measurement errors in successive clinic visits are uncorrelated
- The measurement covariance matrix **R** is diagonal

Remarks on ingredient #5, the forward operator

• H is the fifth component of the model state vector x

• Minimize the objective function

$$\widehat{J}(\mathbf{w}) = (k-1)^{-1}\mathbf{w}^{\mathrm{T}}\mathbf{w} + [\mathbf{y} - \overline{\mathbf{y}}_{b} - \mathbf{Y}_{b}\mathbf{w}]^{\mathrm{T}}\mathbf{R}^{-1}[\mathbf{y} - \overline{\mathbf{y}}_{b} - \mathbf{Y}_{b}\mathbf{w}]$$

• Minimize the objective function

$$\widehat{J}(\mathbf{w}) = (k-1)^{-1} \mathbf{w}^{\mathrm{T}} \mathbf{w} + [\mathbf{y} - \overline{\mathbf{y}}_b - \mathbf{Y}_b \mathbf{w}]^{\mathrm{T}} \mathbf{R}^{-1} [\mathbf{y} - \overline{\mathbf{y}}_b - \mathbf{Y}_b \mathbf{w}]$$

• The minimizer is the k-vector $\mathbf{w}_a = \mathbf{Q}\mathbf{Y}_b^{\mathrm{T}}\mathbf{R}^{-1}(\mathbf{y} - \bar{\mathbf{y}}_b)$ where $\mathbf{Q} = [(k-1)\mathbf{I} + \mathbf{Y}_b^{\mathrm{T}}\mathbf{R}^{-1}\mathbf{Y}_b]^{-1}$ • First update the ensemble mean:

$$\bar{\mathbf{x}}_a = \bar{\mathbf{x}}_b + \mathbf{X}_b \mathbf{w}_a$$

• Then update the analysis ensemble:

 $\mathbf{X}_a = \mathbf{X}_b \mathbf{W}_a$

where $\mathbf{W}_a = [(k-1)\mathbf{Q}]^{1/2}$ (symmetric square root)

- We obtain \mathbf{x}_a^i by adding $\mathbf{\bar{x}}_a$ to the *i* th column of \mathbf{X}_a
- The analysis covariance matrix is $\mathbf{P}_a = \mathbf{X}_b \mathbf{Q} \mathbf{X}_b^{\mathrm{T}}$

- Step 1: Make an ensemble of forecasts ("background") from a set of reasonable initial conditions from $t = t_n$ to $t = t_{n+1}$, the next observation time
- Step 2: At *t*_{*n*+1}, collect a set of observations (PSA levels)
- Step 3: Update the forecast ensemble with the Kalman estimate
- Step 4: $n \leftarrow n + 1$ and go back to Step 1
- Typically (but not always!) $t_{n+1} t_n = 1$ month

Sample result—Serum PSA for Case 4



Blue curve: ensemble mean of model PSA levels
Red circles: clinical measurements

Case 4 PSA ensemble



Case 4 cell population means



• Blue: AD cells; Red: AI cells

• Prediction: Another round of therapy will work

Why do we get two different predictions?

- The state vector involves two tumor subpopulations and associated cell quotas, plus PSA
- The only component that is directly observable is PSA
- PSA production: $P' = \sigma_1(Q_1)X_1 + \sigma_2(Q_2)X_2 \delta P$
- The cell quotas Q_i depend on serum androgen A, which is roughly constant except immediately before and after suppression therapy
- Net result: PSA levels do not depend uniquely on X_1 and X_2
- Thus, the tumor subpopulations are unidentifiable from PSA levels alone!

- The Local Ensemble Transform Kalman Filter is a flexible tool that accounts for empirical model and observational uncertainty
- One's ability to estimate the state of a process depends on the dynamical model and on the measurements
- Caveat: If the ensemble covariance does not accurately reflect the actual model uncertainties, then the filter can diverge

- George Box: "Essentially, all models are wrong, but some are useful"
- Models are most useful when they are designed with the observables in mind
- Open problems include how best to handle model errors
- Prostate tumor cells may dedifferentiate
- As the disease progresses, patients may have large tumors that produce very little PSA

- Mathematical details: B. R. Hunt, E. K., I. Szunyogh, *Physica D* **230** (2007) 112–126
- Portz model: T. Portz, Y. Kuang and J. D. Nagy, *AIP Advances* 2 (2012), 011002